NCT04522739View on ClinicalTrials.gov

Spironolactone Safety in African Americans with Mild Cognitive Impairment and Early Dementia

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Interventions
DRUG

Spironolactone

Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.

DRUG

Placebo

A placebo to match spironolactone will be taken orally once per day for 12 months.

Trial Locations (1)

30329

Emory Clinic at Executive Park, Atlanta

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

Emory University

OTHER

NCT04522739 - Spironolactone Safety in African Americans with Mild Cognitive Impairment and Early Dementia | Biotech Hunter | Biotech Hunter